Online inquiry

IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4243MR)

This product GTTS-WQ4243MR is a type of mRNA modified with 5-Methoxy-UTP, which ecodes the monoclonal antibody that targets Factor VIII substitute gene. The antibody can be applied in Hemophilia A research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000132.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2157
UniProt ID P00451
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ4243MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2395MR IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 110
GTTS-WQ2143MR IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ALD-403
GTTS-WQ9167MR IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMGN-529
GTTS-WQ6542MR IVTScrip™ mRNA-Anti-TNF, D2E7(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA D2E7
GTTS-WQ9168MR IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMGN-529
GTTS-WQ5103MR IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Campath-1H
GTTS-WQ13057MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PEG-IFN-SA
GTTS-WQ3038MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Anti-PTK7 ADC
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW